All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer.   View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Phase I study evaluating brentuximab vedotin and CHP in PTCL

By Sylvia Agathou

Share:

Apr 11, 2018


In March 2018, Michelle Fanale from the University of Texas MD Anderson Cancer Center, Houston, TX, and colleagues, published online in Blood, results from the phase I trial that evaluated the use of brentuximab vedotin (BV) and cyclophosphamide, doxorubicin, and prednisone (CHP), in CD30-expressing peripheral T-cell lymphoma (PTCL) patients.

BV is a CD30-directed antibody that has been successfully used as monotherapy across various PTCL subtypes. It is worth mentioning that, a phase III trial comparing frontline BV + CHP to CHOP for PTCL is ongoing (ECHELON-2; NCT01777152). In this study, the 5-year durability of response, overall survival (OS) and peripheral neuropathy occurrence after BV + CHP was summarized in CD30-expressing PTCL patients, who remained in remission with no additional therapy.

Patient characteristics & study design

  • N = 26 treatment-naïve patients with CD30-expressing PTCL
  • Patient diagnosis:
    • Systemic anaplastic large cell lymphoma (ALCL): n = 19
    • CD30+ PTCL: n = 7
  • n = 13 patients in remission with no additional therapy
  • Dosing (once every 3 weeks):
    • BV: 1.8 mg/kg intravenously (two cycles)
    • CHP: standard CHOP dose intravenously (six cycles)
    • After 6 cycles, patients with objective response (OR) could receive up to 10 cycles of BV monotherapy
    • Median BV cycle administration (range): 13 (3–16)

Key findings

  • All patients achieved OR (100%; 24 complete responses [CR], 2 partial responses [PR])
  • Median observation time (range): 59.6 (4.6–66.0) months (5 years)
  • At 5-year follow-up:
    • Median OS: not reached
    • Estimated 5-year OS: 80% (95% CI, 59–91)
    • 50% of the patients were in remission with no additional therapy and all of then achieved CR (n = 13)
    • Patients remaining in remission had received a median of 16 treatment cycles, as opposed to a median of 10 cycles for the other patients
  • Peripheral neuropathy (PN) occurred in 73% (n = 19) of the total patient population and in 92% (n = 12) of patients in remission
  • Median time to any grade PN onset (range): 11 (0–34) weeks
  • PN treatment resolution or improvement occurred in 95% of the patients (n =18/19) with a median time of 4.2 and 2.6 months, respectively
  • Ongoing PN at last follow-up in 53% of the patients (n = 10)

This long-term evaluation of the BV + CHP regimen in PTCL, demonstrated that of the 100% of the patients responding to the treatment initially, 50% stayed in remission without the use of any other cancer treatment, at 5-year follow-up. Moreover, despite PN occurrence in 73% of the patients, this resolved or improved with PN-targeted treatment in 95% of the cases. The authors concluded that the duration of response and favorable safety profile of BV + CHP, makes this regimen comparable to anthracycline-based therapies combined with consolidative stem cell transplants.

References

Your opinion matters

Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?